52-week rangeThe lowest and highest prices the stock traded at over the last year, from each day's intraday low and high. The marker is today's close: 0% means it sits at the year's low, 100% at the high. It describes where the price is, not where it is going.83.9% up the range
Rs 3,481Rs 5,250
What Torrent Pharmaceuticals does
A short, human-reviewed summary of the business, written from public sources. Background, not analysis, and not updated intraday.
business summary
Unlike many Indian pharma exporters, Torrent earns most of its profit from branded, doctor-prescribed drugs sold inside India rather than commodity generics abroad, giving it some of the sector's highest margins. In July 2026 it completed its merger with rival J B Chemicals, agreed with KKR in 2025, adding cardiology brands and CDMO capability, and it was an early mover in India's generic semaglutide market.
Branded generic formulations in cardiovascular, central nervous system, gastro-intestinal, diabetes, pain management, gynaecology and dermatology, sold mainly in India and Brazil, plus a growing US generics business.
3
3Who buys it
Mostly retail patients in India buying through pharmacies on a doctor's prescription, plus growing patient bases in Brazil and the US, with new markets like ophthalmology added through the JB Chemicals deal.
4
4How it earns
Builds brand loyalty with doctors so patients keep buying the same drug by name rather than switching to the cheapest equivalent, which supports higher margins than plain generics. Profit depends on continued India brand strength, new chronic-therapy launches, and how well the large JB Chemicals acquisition integrates.
Implied vs realized volatility
This compares the volatility options are pricing (from the chain) with the volatility the stock has actually delivered. It appears once the live options chain is available.
options live in market hours
The options-implied volatility comes from the live chain, which is available during and around market hours (9:15-3:30 IST, Mon-Fri). The stock has realized 18.1% volatility over the last 30 days; the implied figure and the comparison will show when the chain is live.
TORNTPHARM price vs the biggest options level
The daily candles are the actual stock. The two labeled lines are the single strike with the most call open interest (a resistance level option sellers are defending) and the single strike with the most put open interest (a support level). The full breakdown across every strike is in the Open Interest Profile card below.
EOD 11 Sept
IndicatorsVolume
Loading TORNTPHARM price...
Options snapshot
The live stock option chain (PCR, max pain, expected move, OI) loads during and around market hours.
live in market hours
TORNTPHARM's live option chain - put-call ratio, max pain, expected move and open-interest walls - appears during market hours (9:15-3:30 IST, Mon-Fri). Come back when the market is open for the full options view.
Returns and valuation
Built from the company's own balance sheet and cash flow. Return on equity is the trailing twelve months of profit against the equity on the books; the balance sheet behind it is filed twice a year, not four times.
from the filing as at 2026-03-31
Market cap
Rs 1,68,062 Cr
what the whole company is priced at today
Return on equity
12.3%
profit earned on every Rs 100 of shareholders money
Price to book
20.03x
20.03 times the value on its own books
Return on assets
4.9%
profit against everything it owns
Return on capital
9.1%
EV / EBITDA
41.3x
Dividend yield
0.77%
paid out on today's price
Book value / share
Rs 248
the company's own books, per share
What it owns and what it owes
Straight from the balance sheet in the company's filing. Net debt is borrowings less cash and liquid investments, so a negative figure means it holds more cash than debt.
as at 2026-03-31
Total assets
Rs 44,312 Cr
everything the company owns
Shareholders equity
Rs 17,585 Cr
40% of what it owns is funded by its owners
Cash and equivalents
Rs 1,117 Cr
cash and near-cash on hand
Net debt
Rs 12,815 Cr
borrowings less cash
Debt to equity
0.84x
borrowings against the owners' money
Current ratio
1.13x
short-term assets against short-term dues
Companies file a balance sheet twice a year, not every quarter, so this is the most recent one published rather than the latest quarter.
The cash it actually made
Profit is an accounting figure; cash flow is what moved. Free cash flow is the cash from running the business less what was spent on plant and equipment, so it is what was left over to pay down debt or return to shareholders.
year to 2026-03-31
Cash from operations
Rs 3,023 Cr
cash the business itself threw off
Free cash flow
Rs 2,346 Cr
what was left after spending on the business
FCF margin
16.8%
free cash for every Rs 100 of sales
Cash vs profit
1.41x
every rupee of profit arrived as cash, or more
Cash flow is reported for the year to date, so this covers the full period ending 2026-03-31 rather than a single quarter.
Fundamentals
Trailing-twelve-month valuation, margins and growth from the company's own filings.
as of 2026-06-30
P/E (TTM)
79.3
PEG
24.18
EPS (TTM)
Rs 62.6
Net margin
13.7%
Rev growth YoY
+54.85%
Profit growth YoY
+3.28%
TTM revenue
Rs 15,723 Cr
TTM net profit
Rs 2,156 Cr
Against its sector
Where this stock sits within its own sector on each measure. The marker is its position in the peer group and the notch is the sector median. A position is a fact about the cohort, not a view on the stock.
Median rather than average, so one loss-making or one very expensive peer cannot drag the reference. Valuation is shown without a colour verdict: a higher multiple can mean expensive, or faster growth expected, and only you can decide which.
The business
Sales and net profit from the company's own filings, by financial year or by quarter. Hover any bar for that period's complete figures including operating margin and the change against the comparable earlier period. The single TTM figure above is the sum of the last four quarters.
5 years · 20 quarters
Full financial years - the long arc of the business.
Sales growth
+14.9%
a year, 3 years
Profit growth
+20.9%
a year, 3 years
Operating margin
32.6%
latest year
Sales by financial yearRs 13,980 Cr
Net profit by financial yearRs 2,138 Cr
FY225 full years · hover a yearFY26
Operating margin has gone from 28.6% to 32.6% over these years - the share of every rupee of sales kept after running costs, before interest and tax. Full financial years only, so a part-year is never shown as a whole one. Hover any year for its complete figures.
Dividends paid
Cash paid per share, from the exchange's corporate-action record, restated to today's share count across bonuses and splits. Dates shown are ex-dates: you must own the shares before that date to receive the payment.
0.77% yield
Rs 770 / year
Paid 11 of 11 yrs
on Rs 1 lakh at today's price · 0.77% yield · Rs 38/share
What each year paid, on Rs 1 lakh
141
141
171
171
352
252
443
564
644
765
17
18
19
20
21
22
23
24
25
26*
* 2026 so far - more may still be declared this year
2026 has paid Rs 38.00 per share, about Rs 765 on Rs 1 lakh at today's price. Earlier years are restated to today's share count, so a bonus or split never reads as a dividend cut. Dividends are at the company's discretion and can be cut or skipped.
Technical snapshot
Momentum, trend and delivery-based conviction from the actual price and volume history.
EOD 11 Sept
RSI (14) - momentum
52.2Neutral
0 oversold3070overbought 100
Delivery % - genuine buying vs churn
58.9%Near average
today 58.9%20d avg 60.1%
The share of traded quantity that was actually delivered (not squared off intraday) - high delivery vs its 20-session average suggests real buying or holding, not just churn.
vs 50-DMA
+0.36%
vs 200-DMA
+13.80%
1-month
+1.04%
3-month
+9.98%
1-year
+38.74%
Realized vol (30d)
18.1%
Insider trading disclosures
Promoter, director and other insider trades in the company's own shares, as disclosed to the exchange under SEBI's insider-trading regulations - usually within a few days of the transaction.
last 18 months
Insider trading data unavailable.
Recent announcements
The company's own filings to the exchange - results, board meetings, investor calls - with a link to the source document.
last 6 months
Announcements unavailable.
Want to test a strategy on TORNTPHARM?
Backtest an equity strategy on real market data, free - no card needed.
Equity price, fundamentals and realized volatility are end-of-day / quarterly from real market data. The option chain (PCR, max pain, expected move, IV, OI) is live from the exchange during market hours; outside them it shows the last session's close. Shareholding, insider trades and announcements are the company's own exchange filings. Analysis only, not investment advice.